Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 86

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 2
Chunk 86
---
 85,659   22,772   442,755                  OPERATING EXPENSES                Sales and marketing  (30,211)  (508,683)  (24,625)  (1,195,502)Research and development  (14,876)  -   (10,442)  - General and administrative  (55,835)  (205,740)  (255,477)  (175,667)Fair value loss on investments in equity securities  -   -   -   (79,000)Provision for expected credit losses   -   (175,818)  -   (2,374)TOTAL OPERATING EXPENSES  (100,922)  (890,241)  (290,544)  (1,452,543)                 LOSS FROM OPERATIONS  (74,917)  (430,801)  (267,327)  (683,697)                 FINANCE COSTS  (3,115)  (3,165)  (3,764)  (2,415)                 LOSS BEFORE TAX  (78,032)  (433,966)  (271,091)  (686,112)                 Tax expense  -   -   -   (1,555)                 NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS  $(78,032) $(433,966) $(271,091) $(687,667)

 38Table of Contents

Revenue. For the current quarter ended September 30, 2025, we had total revenue of $2,543,823 as compared to total revenue of $2,630,376 for the same quarter in the previous year. This represents a decrease of 3.3% for the reasons discussed below.

MRNA Scientific contributed $4,768 (0.2%) of the total revenue for the current quarter ended September 30, 2025, as compared to revenue of $2,563 (0.1%) of the total revenue from the same quarter in the previous year, representing an increase of 86%. The increase in revenue was mainly attributable to more client referrals from diagnostic centers.